Loading...
•
Dec 31, 2023
Omeros Q4 2023 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2023.
Key Takeaways
Omeros Corporation reported a net loss of $9.1 million for Q4 2023, compared to a net loss of $37.8 million for the third quarter of 2023. The company's cash used in operations for the fourth quarter was $34.8 million. They received $115.5 million from DRI in February 2024.
Net loss for the fourth quarter of 2023 was $9.1 million, or $0.15 per share.
Omeros and DRI Healthcare Acquisitions LP amended the OMIDRIA royalty purchase agreement, resulting in Omeros receiving $115.5 million in cash.
At December 31, 2023, Omeros had $171.8 million of cash and short-term investments available.
Omeros continues to engage with FDA regarding the planned resubmission of its Biologics License Application for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Forward Guidance
Omeros expects its first quarter net loss to be $34.0 to $37.0 million or $0.58 to $0.63 loss per share. As of March 31, 2024, we expect our cash and investments balance available for operations and debt service to be approximately $230.0 million after repurchasing 3.2 million shares of our outstanding common stock for $11.9 million during the first quarter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...